Biotechnology Development Program

Lupin’s 200+ strong Biotechnology Group has developed a robust pipeline of biosimilars addressing therapies like Oncology, Anti-Inflammatory, Anti-Virals, Rheumatoid Arthritis, Endocrinology, Diabetes, Ophthalmology and Women’s Health.

Over the last 8 years, the Company has gained deep insight in terms of product development, market intelligence regulatory and Intellectual Property.

Highlights for FY 2016

  • Successful commercialization of its first two Oncology biosimilars in India - Lupifil® (Filgrastim) and Lupifil-P® (Peg-Filgrastim) in India
  • Global Phase III comparative clinical trial for Etanercept on track across geographies such as Japan and multiple countries within the European Union
  • Completed Phase-I PK/PD trial for 2 products and pre-clinical studies for 2 products in India
  • Scale-up and technology transfer for 5 products successfully mediated from research to commercial

The Company is also making significant investments to augment its Biotech Manufacturing and R&D infrastructure. Lupin’s own fill finish facility is expected to be operational in FY 2017.